Vitamin D and the cardiovascular system

Clinical Journal of the American Society of Nephrology

Volumn 4, Issue 9, 2009, Pages 1515-1522

  Artaza, Jorge N ^a,b   Mehrotra, Rajnish ^b,c   Norris, Keith C ^a,b,c  

^a CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; BONE MORPHOGENETIC PROTEIN 2; CALCITRIOL; CALCIUM; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CYCLIN A1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN E; FOLLISTATIN; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; NEUTROPHIL COLLAGENASE; OSTEOGENIC PROTEIN 1; PARICALCITOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; RENIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VITAMIN D; VITAMIN D RECEPTOR;

APOPTOSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL CYCLE ARREST; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG MECHANISM; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART PROTECTION; HEMODIALYSIS; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; KIDNEY FAILURE; MONOTHERAPY; MORTALITY; NONHUMAN; OBESITY; PROTEIN EXPRESSION; RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

ADULT; ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CHRONIC DISEASE; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY DISEASES; NUTRITION POLICY; RISK ASSESSMENT; RISK FACTORS; SIGNAL TRANSDUCTION; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 70350398576     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02260409     Document Type: Review

References (60)

1. Holick MF: The vitamin D epidemic and its health consequences. J Nutr 135: 2739S-2748S, 2005
2. Holick MF: Vitamin D deficiency. N Engl J Med 357: 266-281, 2007
3. Rostand SG: Ultraviolet light may contribute to geographic and racial blood pressure differences. Hypertension 30: 150-156, 1997
4. Yuan W, Pan W, Kong J, Zheng W, Szeto FL, Wong KE, Cohen R, Klopot A, Zhang Z, Li YC: 1,25-Dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem 282: 29821-29830, 2007
5. Revelli A, Massobrio M, Tesarik J: Nongenomic effects of 1alpha,25-dihydroxyvitamin d(3). Trends Endocrinol Metab 9: 419-427, 1998
6. Zanello LP, Norman A: 1Alpha,25(OH)2 vitamin D3 actions on ion channels in osteoblasts. Steroids 71: 291-297, 2006
7. Dusso AS, Brown AJ, Slatopolsky E: Vitamin D. Am J Physiol Renal Physiol 289: F8-F28, 2005
8. Al-Badr W, Martin KJ: Vitamin D and kidney disease. Clin J Am Soc Nephrol 3: 1555-1560, 2008
9. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, Wu K, Meinken C, Kamen DL, Wagner M, Bals R, Steinmeyer A, Zugel U, Gallo RL, Eisenberg D, Hewison M, Hollis BW, Adams JS, Bloom BR, Modlin RL: Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311: 1770-1773, 2006
10. Saggese G, Federico G, Balestri M, Toniolo A: Calcitriol inhibits the PHA-induced production of IL-2 and IFN-gamma and the proliferation of human peripheral blood leukocytes while enhancing the surface expression of HLA class II molecules. J Endocrinol Invest 12: 329-335, 1989
11. Tan X, Li Y, Liu Y: Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 17: 3382-3393, 2006
12. Wu-Wong JR, Nakane M, Ma J: Effects of vitamin D analogs on the expression of plasminogen activator inhibitor-1 in human vascular cells. Thromb Res 118: 709-714, 2006
13. Zhang Z, Sun L, Wang Y, Ning G, Minto AW, Kong J, Quigg RJ, Li YC: Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int 73: 163-171, 2008
14. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP: 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110: 229-238, 2002
15. Artaza JN, Norris KC: Vitamin D reduces the expression of collagen and key profibrotic factors by inducing an antifibrotic phenotype in mesenchymal multipotent cells. J Endocrinol 200: 207-221, 2009
16. Scragg R, Jackson R, Holdaway IM, Lim T, Beaglehole R: Myocardial infarction is inversely associated with plasma 25-hydroxyvitamin D3 levels: A community-based study. Int J Epidemiol 19: 559-563, 1990
17. Scragg R, Holdaway I, Jackson R, Lim T: Plasma 25-hydroxyvitamin D3 and its relation to physical activity and other heart disease risk factors in the general population. Ann Epidemiol 2: 697-703, 1992
18. Martins D, Wolf M, Pan D, Zadshir A, Tareen N, Thadhani R, Felsenfeld A, Levine B, Mehrotra R, Norris K: Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: Data from the Third National Health and Nutrition Examination Survey. Arch Intern Med 167: 1159-1165, 2007
19. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin EJ, D'Agostino RB, Wolf M, Vasan RS: Vitamin D deficiency and risk of cardiovascular disease. Circulation 117: 503-511, 2008
20. Melamed ML, Michos ED, Post W, Astor B: 25-Hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 168: 1629-1637, 2008
21. Dobnig H, Pilz S, Scharnagl H, Renner W, Seelhorst U, Wellnitz B, Kinkeldei J, Boehm BO, Weihrauch G, Maerz W: Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med 168: 1340-1349, 2008
22. Pfeifer M, Begerow B, Minne HW, Nachtigall D, Hansen C: Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab 86: 1633-1637, 2001
23. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW, American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention: Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108: 2154-2169, 2003
24. Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P, Williams L, Batlle D: Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 68: 2823-2828, 2005
25. Shoben AB, Rudser KD, de Boer IH, Young B, Kestenbaum B: Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 19: 1613-1619, 2008
26. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K: Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 168: 397-403, 2008
27. Kovesdy CP, Kalantar-Zadeh K: Vitamin D receptor activation and survival in chronic kidney disease. Kidney Int 73: 1355-1363, 2008
28. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA Jr, Thadhani R: Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 16: 1115-1125, 2005
29. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, McAllister CJ, Budoff MJ, Salusky IB, Kopple JD: Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70: 771-780, 2006
30. Wolf M, Betancourt J, Chang Y, Shah A, Teng M, Tamez H, Gutierrez O, Camargo CA Jr, Melamed M, Norris K, Stampfer MJ, Powe NR, Thadhani R: Impact of activated vitamin D and race on survival among hemodialysis patients. J Am Soc Nephrol 19: 1379-1388, 2008
31. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Cataliotti A, Seminara G, Stancanelli B, Malatino LS: Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol 12: 2768-2774, 2001
32. Hunter JJ, Chien KR: Signalling pathways for cardiac hypertrophy and failure. N Engl J Med 341: 1276-1282, 1999
33. Middleton RJ, Parfrey PS, Foley RN: Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol 12: 1079-1084, 2001
34. Zoccali C, Mallamaci F, Maas R, Benedetto FA, Tripepi G, Malatino LS, Cataliotti A, Bellanuova I, Boger R: Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int 62: 339-345, 2002
35. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL: Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int 71: 31-38, 2007
36. Park CW, Oh YS, Shin YS, Kim CM, Kim YS, Kim SY, Choi EJ, Chang YS, Bang BK: Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 33: 73-81, 1999
37. Kim HW, Park CW, Shin YS, Kim YS, Shin SJ, Kim YS, Choi EJ, Chang YS, Bang BK: Calcitriol regresses cardiac hypertrophy and QT dispersion in secondary hyperparathyroidism on hemodialysis. Nephron Clin Pract 102: c21-c29, 2006
38. Xiang W, Kong J, Chen S, Cao LP, Qiao G, Zheng W, Liu W, Li X, Gardner DG, Li YC: Cardiac hypertrophy in vitamin D receptor knockout mice: Role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 288: E125-E132, 2005
39. Wu J, Garami M, Cheng T, Gardner DG: 1,25(OH)2 vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. J Clin Invest 97: 1577-1588, 1996
40. Nibbelink KA, Tishkoff DX, Hershey SD, Rahman A, Simpson RU: 1,25(OH)2-vitamin D3 actions on cell proliferation, size, gene expression, and receptor localization, in the HL-1 cardiac myocyte. J Steroid Biochem Mol Biol 103: 533-537, 2007
41. Bodyak N, Ayus JC, Achinger S, Shivalingappa V, Ke Q, Chen YS, Rigor DL, Stillman I, Tamez H, Kroeger PE, Wu-Wong RR, Karumanchi SA, Thadhani R, Kang PM: Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A 104: 16810-16815, 2007
42. Artaza JN, Norris KC: VD (1,25D) inhibits cardiomyoblasts cell proliferation by promoting cell cycle arrest and enhances cardiomyotubes formation without inducing apoptosis [Abstract]. J Investig Med 57: 112, 2009
43. Andress DL: Vitamin D in chronic kidney disease: A systemic role for selective vitamin D receptor activation. Kidney Int 69: 33-43, 2006
44. Sun J, Kong J, Duan Y, Szeto FL, Liao A, Madara JL, Li YC: Increased NF-kB activity in fibroblasts lacking the vitamin D receptor. Am J Physiol Endocrinol Metab 291: E315-E322, 2006
45. Rabbany SY, Heissig B, Hattori K, Rafii S: Molecular pathways regulating mobilization of marrow-derived stem cells for tissue revascularization. Trends Mol Med 9: 109-117, 2003
46. Mathew S, Lund RJ, Chaudhary LR, Geurs T, Hruska KA: Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol 19: 1509-1519, 2008
47. Hsu JJ, Tintut Y, Demer LL: Vitamin D and osteogenic differentiation in the artery wall. Clin J Am Soc Nephrol 3: 1542-1547, 2008
48. Shao JS, Cheng SL, Pingsterhaus JM, Charlton-Kachigian N, Loewy AP, Towler DA: Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest 115: 1210-1220, 2005
49. Melamed ML, Muntner P, Michos ED, Uribarri J, Weber C, Sharma J, Raggi P: Serum 25-hydroxyvitamin D levels and the prevalence of peripheral arterial disease: Results from NHANES 2001 to 2004. Arterioscler Thromb Vasc Biol 28: 1179-1185, 2008
50. Fahrleitner-Pammer A, Obernosterer A, Pilger E, Dobnig H, Dimai HP, Leb G, Kudlacek S, Obermayer-Pietsch BM: Hypovitaminosis D, impaired bone turnover and low bone mass are common in patients with peripheral arterial disease. Osteoporos Int 16: 319-324, 2005 Mar.
51. Fahrleitner A, Dobnig H, Obernosterer A, Pilger E, Leb G, Weber K, Kudlacek S, Obermayer-Pietsch BM: Vitamin D deficiency and secondary hyperparathyroidism are common complications in patients with peripheral arterial disease. J Gen Intern Med 17: 663-669, 2002
52. Aschenbrenner JK, Sollinger HW, Becker BN, Hullett DA: 1,25-(OH(2))D(3) alters the transforming growth factor beta signaling pathway in renal tissue. J Surg Res 100: 171-175, 2001
53. Heaney RP: Vitamin D in health and disease. Clin J Am Soc Nephrol 3: 1535-1541, 2008
54. Andress D: Nonclassical aspects of differential vitamin D receptor activation: Implications for survival in patients with chronic kidney disease. Drugs 67: 1999-2012, 2007
55. Li AC, Glass CK: The macrophage foam cell as a target for therapeutic intervention. Nat Med 8: 1235-1242, 2002
56. Giovannucci E, Liu Y, Hollis BW, Rimm EB: 25-Hydroxyvitamin D and risk of myocardial infarction in men: A prospective study. Arch Intern Med 168: 1174-1180, 2008
57. Pilz S, März W, Wellnitz B, Seelhorst U, Fahrleitner-Pammer A, Dimai HP, Boehm BO, Dobnig H: Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J Clin Endocrinol Metab 93: 3927-3935, 2008
58. Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, Steele D, Chang Y, Camargo CA Jr, Tonelli M, Thadhani R: Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 72: 1004-1013, 2007
59. Wang AY, Lam CW, Sanderson JE, Wang M, Chan IH, Lui SF, Sea MM, Woo J: Serum 25-hydroxyvitamin D status and cardiovascular outcomes in chronic peritoneal dialysis patients: A 3-y prospective cohort study. Am J Clin Nutr 87: 1631-1638, 2008
60. Ravani P, Malberti F, Tripepi G, Pecchini P, Cutrupi S, Pizzini P, Mallamaci F, Zoccali C: Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 75: 88-95, 2009